LivaNova PLC Ordinary Shares
LIVNLivaNova PLC is a global medical device company specializing in innovative solutions for cardiac and neurological conditions. Founded in 2018 through the merger of Sorin Group and Cyberonics, the company focuses on developing and manufacturing devices for cardiac surgery, neuromodulation, and neurocritical care, aiming to improve patient outcomes and quality of life.
Company News
The global ECMO machine market is projected to grow from USD 495 million in 2025 to USD 725.99 million by 2033 at a CAGR of 4.91%, driven by rising respiratory and cardiac conditions and expanding critical care infrastructure. However, high costs, complex operations, and regulatory challenges pose barriers to market expansion. North America leads...
The global magnetic ablation catheters market is expected to grow significantly, reaching $1.1 billion by 2035, driven by advancements in technology and the rising prevalence of cardiovascular diseases. Key factors driving growth include the increasing adoption of minimally invasive procedures and continued investment in healthcare infrastructure...
The cardiac resynchronization therapy market is expected to grow at a CAGR of 6.49% from 2024 to 2030, driven by increasing cardiovascular disorders, innovative product developments, and the rising geriatric population. North America is expected to dominate the market during the forecast period.
The global blood recovery machine market is expected to grow at a CAGR of 5.9% from 2024 to 2033, driven by advancements in medical technologies, increased awareness of autologous blood transfusion benefits, and rising demand for surgical procedures.
The global electrotherapy system market is expected to grow from $1.15 billion in 2023 to $1.65 billion by 2030, driven by advancements in technology and increasing demand for non-invasive treatment options. The TENS segment dominates the market, particularly for chronic pain management.
